SB 202190 is a DFG inhibitor used in the treatment of colorectal cancer. It is a highly selective, potent inhibitor of p38 MAP kinase. SB-202190 is able to promote proliferation of C6 cells in lower concentration but induced apoptosis in higher levels. Studies show that SB202190 can protect neural function from ischemia/reperfusion injury and regulate the activation of Bcl-2 and Bax protein after ischemia/reperfusion in rat.

CAS：152121-30-7
中文别名：4-(4-氟苯基)-2-(4-羟基苯基)-5-(4-吡啶基)-1H-咪唑;4-[4-(4-氟苯基)-5-(4-吡啶基)-1H-咪唑-2-基]-苯酚;
英文别名：4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one;4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole;FHPI;
分子式：C20H14FN3O
分子量：331.343
精确质量：331.112
Psa：61.8
Logp：4.6504

MDL号：MFCD00941964

外观与性状：淡黄色
密度：1.311g/cm3
沸点：565.705ºC at 760 mmHg
闪点：295.928ºC
折射率：1.653
蒸汽压：0mmHg at 25°C

安全说明：S26-S36/37
危险类别码：R36/37/38
危险品标志：Xi